| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2050000 | FEBS Letters | 2008 | 6 Pages |
AML1-ETO fusion protein is observed in approximately 12% of acute myeloid leukemia. In the present research, we found that AML1-ETO is able to inhibit Sp1 transactivity. We also found that this inhibition of Sp1 transactivity by AML1-ETO is achieved by interaction between Sp1 and RUNT domain of AML1. AML1b is able to abrogate the inhibition of AML1-ETO. Since Sp1 is involved in hematopoietic cell differentiation, we proposed that AML1-ETO promotes leukemogenesis by blocking cell differentiation through inhibition of Sp1 transactivity.Structured summaryMINT-6549474: AML1-ETO (genbank_protein_gi:AAB34820) physically interacts (MI:0218) with Sp1 (uniprotkb:P08047) by anti bait coimmunoprecipitation (MI:0006)MINT-6549439: Sp1 (uniprotkb:P08047) physically interacts (MI:0218) with AML1-ETO (uniprotkb:AAB34820) by anti tag coimmunoprecipitation (MI:0007)MINT-6549458: Sp1 (uniprotkb:P08047) physically interacts (MI:0218) with AML1a (uniprotkb:Q01196-2) by anti tag coimmunoprecipitation (MI:0007)
